Holen Sie sich die Stockscreener-App
0.344
5.74%
-0.0209
Handel nachbörslich:
.35
0.006
+1.74%
Schlusskurs vom Vortag:
$0.3649
Offen:
$0.385
24-Stunden-Volumen:
434.57K
Relative Volume:
0.90
Marktkapitalisierung:
$7.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.21M
KGV:
-0.044
EPS:
-7.82
Netto-Cashflow:
$-44.62M
1W Leistung:
-9.59%
1M Leistung:
-5.57%
6M Leistung:
-70.85%
1J Leistung:
-87.97%
1-Tages-Spanne:
$0.34
$0.386
1-Wochen-Bereich:
$0.34
$0.412
52-Wochen-Spanne:
$0.33
$2.9077
Aptose Biosciences Inc Stock (APTO) Company Profile
Firmenname
Aptose Biosciences Inc
Sektor
Branche
Telefon
310-849-8060
Adresse
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
Vergleichen Sie APTO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| APTO | 0.344 | 7.38M | 0 | -51.21M | -44.62M | -7.82 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-10-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-02-20 | Eingeleitet | Maxim Group | Buy |
| 2020-02-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-16 | Eingeleitet | B. Riley FBR | Buy |
| 2017-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-23 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2017-06-08 | Eingeleitet | Rodman & Renshaw | Neutral |
Alle ansehen
Aptose Biosciences Inc Aktie (APTO) Neueste Nachrichten
ARMISTICE CAPITAL, LLC Increases Stake in Aptose Biosciences Inc - GuruFocus.com
Aptose Biosciences Inc. (APTO) Quarterly 10-Q Report - Quartzy
Aptose Biosciences Reports Q3 2024 Financial Highlights - TipRanks
Aptose Reports Results for the Third Quarter 2024 - GlobeNewswire
Aptose Biosciences Cuts Q3 Losses, Secures $10M Loan Amid Nasdaq Challenges | APTO Stock News - StockTitan
Aptose Biosciences faces delisting from NASDAQ - Investing.com India
Aptose Biosciences faces delisting from NASDAQ By Investing.com - Investing.com South Africa
Analysts’ New Coverage for September 18th (AINC, AIRI, APTO, ARM, AVGO, BGNE, CAN, CARA, CHH, CLLS) - Defense World
Aptose Biosciences secures shareholder nod for warrant issuance - Investing.com
Aptose Biosciences stock hits 52-week low at $0.34 - Investing.com
Aptose Biosciences Shareholders Endorse Key Resolutions - TipRanks
Aptose Announces Results from Special Meeting of Shareholders - GlobeNewswire
A significant driver of top-line growth: Aptose Biosciences Inc (APTO) - SETE News
Aptose Biosciences Inc Inc. (APTO) Price Performance: A Technical Analysis Perspective - The InvestChronicle
APTO’s earnings forecast for the current quarter - US Post News
Daily Market Movement: Aptose Biosciences Inc (APTO) Sees a 2.19 Increase, Closing at 0.41 - The Dwinnex
Hello Group, Zscaler And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Aptose Biosciences secures funds for AML treatment development - Pharmaceutical Technology
Aptose Biosciences (NASDAQ:APTO) Receives New Coverage from Analysts at StockNews.com - Defense World
Aptose secures $10 million loan for leukemia drug development - Investing.com India
APTOAptose Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Aptose Biosciences Secures Convertible $10M Loan from Hanmi - TipRanks
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib - Yahoo Finance
Aptose Receives $10 Million Through a Facility Agreement - GlobeNewswire
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences stock hits 52-week low at $0.4 amid downturn - Investing.com
APTO’s Market Whiplash: -81.82% YTD Decline, -24.89% Plunge in 30 Days - The InvestChronicle
Market Resilience: Aptose Biosciences Inc (APTO) Finishes Weak at 0.46, Down -4.82 - The Dwinnex
Aptose Biosciences (NASDAQ:APTO) vs. ImmunityBio (NASDAQ:IBRX) Critical Review - Defense World
Aptose Biosciences: Bottom 25 Performing Stocks Year-To-Date On TSX (APS) - Barchart
Aptose Announces Adjournment of its Special Meeting of Shareholders - GlobeNewswire
Aptose Biosciences (NASDAQ:APTO) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS - Defense World
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024 - MSN
Aptose Biosciences: Q2 Earnings Snapshot - Houston Chronicle
Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com - Defense World
Aptose Reports Results for the Second Quarter 2024 - GlobeNewswire
Aptose Biosciences Inc (APS-T) QuotePress Release - The Globe and Mail
Aptose Biosciences stock hits 52-week low at $0.55 amid downturn - Investing.com Australia
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com - Defense World
Caspase 3 Market – 37% of Growth to Originate from APAC -Aptose Biosciences Inc, BeyondSpring Pharmaceuticals Inc, Conat – Moose Gazette - Moose Gazette
Aptose Biosciences Inc. (NASDAQ:APTO) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Finanzdaten der Aptose Biosciences Inc-Aktie (APTO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):